BOUCHERVILLE, QC — December 23, 2025 — Leads & Copy —
LSL Pharma Group Inc. (TSXV: LSL) has finalized its acquisition of Juno OTC Inc. from Juno Pharmaceuticals LP for $5 million. The acquisition, completed on December 23, 2025, includes all outstanding shares of Juno OTC, a Toronto-based subsidiary of Juno Pharmaceuticals LP.
The purchase agreement, dated December 22, 2025, stipulated that $2.5 million was paid in cash on the closing date, with an additional 5,509,642 Class “A” common shares of LSL Pharma issued. A further $500,000 cash payment is due on January 1, 2027, subject to working capital adjustments.
While LSL Pharma now owns all outstanding shares of Juno OTC, Juno Pharmaceuticals LP will maintain operational control until December 31, 2025. LSL Pharma will assume full control on January 1, 2026.
The transaction is at arm’s length and does not involve any finder’s fees. It is classified as an “Expedited Acquisition” under TSXV Policy 5.3 and is pending final approval from the TSXV. Securities issued are subject to a four-month statutory hold period. More details can be found in LSL Pharma’s news releases from December 17 and December 23, 2025.
LSL Pharma also announced the closing of a non-brokered private placement, raising $2 million through the issuance of unsecured convertible debentures. The company issued 2,000 debentures at $1,000 each. The debentures carry a 10.0% annual interest rate, payable semi-annually, and will mature on December 31, 2029. Each debenture is convertible into common shares at $0.45 per share. Juno Pharmaceuticals LP subscribed for $1.5 million in debentures as part of the acquisition agreement.
Including the previously announced $10 million brokered private placement, LSL Pharma has raised a total of $12 million. The company’s December 23, 2025, news release provides further information on the brokered offering.
Juno OTC is a supplier in the Canadian private label consumer healthcare OTC market. The company provides key Canadian retailers with core product offerings under the retailers’ own recognized private label brands. Juno OTC possesses all necessary Health Canada licenses for importing and distributing products, as well as expertise in regulatory and quality assurance.
LSL Pharma Group Inc. specializes in the development, manufacturing, and commercialization of sterile ophthalmic pharmaceutical products, along with pharmaceutical, cosmetic, and natural health products in various dosage forms. Its subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc., Dermolab Pharma Ltd., and Du-Var Laboratory Inc.
Source: LSL Pharma Group Inc.
